Preoperative risk factors for postoperative pneumonia in patients with esophageal cancer: A systematic review and meta-analysis.

Surg TodayJun 3, 2026 (epub)
Clinical ResearchGeneral SurgeryOncology (Medical)Open access

Tsuyoshi Harada, Hiroki Sato, Kazuki Okura et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated preoperative risk factors for postoperative pneumonia in patients undergoing esophagectomy for esophageal cancer. Analyzing 60 studies, it found that physical frailty, sarcopenia, and forced expiratory volume (FEV) were significant predictors of pneumonia, with physical frailty showing the highest odds ratio of 5.170.

Key findings

  • Physical frailty was associated with an odds ratio of 5.170 for postoperative pneumonia.
  • Sarcopenia had an odds ratio of 2.790 for pneumonia risk.
  • Forced expiratory volume (FEV) was linked to an odds ratio of 2.730.

Why it matters

Understanding these risk factors can help clinicians identify high-risk patients and implement targeted preoperative interventions to reduce the incidence of postoperative pneumonia, a significant complication following esophagectomy.

Source

PubMed · PMID 42234145Free full text on PubMed Central

Published in Surg Today. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.